Valence Life Sciences

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.

Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.

Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.

Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.